• SE Formula Biotechnology Commercialisation Ready
• ECO Nurture Kiwifruit Evaluation Complete
• R&D Funding Underpins Development Costs

Skin Elements Limited (ASX: SKN), a world leader in the development of Australian all natural antimicrobial biotechnology, has provided its Quarterly Activity Report for the quarter ending 31 December 2025. Key highlights include: The SE Formula antimicrobial biotechnology formulae continue to meet milestone completions in readiness for initial product commercialisation. Over the past three growing seasons, over 6,400 litres of ECO-Nurture sustainable, horticultural plant biostimulant have been delivered to kiwifruit orchards in New Zealand with positive outcomes, and the company is now seeking to appoint a commercial partner for market rollout. The company received an R&D Rebate of $610k in relation to qualifying R&D expenditure for the FY 2025 year. Skin Elements completed a $2.5 million placement to sophisticated investors, and shareholders approved the issue of securities to a director and key management to settle $1 million in outstanding remuneration. The company's flagship formulations, including the SuprCuvr hospital-grade plant-based disinfectant, ECO-Nurture plant bio-stimulant, Soleo Organics natural sunscreen, PapayaActivs natural therapeutics skincare, and Elizabeth Jane Natural Cosmetics brand, have all completed phase three development and are now being readied for commercialization.

With a robust financial position enhanced by the recent $2.5 million placement, Skin Elements' sales programmes are well positioned to drive growth in 2026. The strong field evaluation outcomes from its SE Formula and ECO Nurture programmes, together with independent verification of its Soleo Organics sunscreen formulations, validate the company's development process and readiness for commercial scale sales.